SYNLOGIC, INC. Contract Liability (Deferred Revenue)
SYNLOGIC, INC. (SYBX) had Contract Liability (Deferred Revenue) of $0 as of 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-03-19
- 2023-12-31: Contract with Customer, Liability, Current $0.00.
- 2023-09-30: Contract with Customer, Liability, Current $264.00K.
- 2023-06-30: Contract with Customer, Liability, Current $657.00K.
- 2023-03-31: Contract with Customer, Liability, Current $692.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-19 |
| 2023-09-30 | $264.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $657.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $692.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $882.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $971.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $149.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $314.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $531.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $988.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $904.00K 10-Q · filed 2021-08-12 |
| 2020-03-31 | $445.00K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $544.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $1.77M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.08M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.96M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $268.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $378.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $179.00K 10-Q · filed 2018-08-09 |
| 2017-12-31 | $444.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |